Pharma in Focus After Hours: Kythera (NASDAQ:KYTH), La Jolla Pharmaceutical (NASDAQ:LJPC), Medifast (NYSE:MED)



Kythera (NASDAQ:KYTH) and Bayer ADR (OTCMRKTS:BAYRY) announced that Kythera acquired all rights outside of the U.S. and Canada to ATX-101, a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat (double chin). In 2010, KYTHERA (NASDAQ:KYTH) licensed the commercial rights to ATX-101 outside of the U.S. and Canada to Bayer Consumer Care AG.

Under the new agreement, Kythera Holdings, a wholly-owned Bermuda subsidiary of Kythera Biopharmaceuticals, acquired rights to develop and commercialize ATX-101 outside the U.S. and Canada. Bayer will receive $33M in KYTHERA (NASDAQ:KYTH) common stock, plus a $51M note, payable no later than 2024. Bayer is also eligible to receive certain long-term sales milestone payments on annual sales outside of the U.S. and Canada.

La Jolla Pharmaceutical (NASDAQ:LJPC) announced top-line results from its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease. The trial met its primary efficacy endpoint of a statistically significant improvement in kidney function. Specifically, a dose of 1.5 mg/m2 led to a statistically significant increase in estimated glomerular filtration rate (eGFR) compared to placebo between baseline and end of treatment. At the 30 mg/m2 dose, there was no statistically significant difference.

Key secondary endpoints were also met, and the effect on circulating galectin-3 levels was consistent with the effect on eGFR. For the 1.5 mg/m2 dose, there was a statistically significant reduction in circulating levels of galectin-3, while there was no significant difference at the 30 mg/m2 dose level. GCS-100 was well-tolerated.

Out of 121 patients enrolled, 117 completed treatment, including all 41 patients treated at the 1.5 mg/m2 dose. There were no serious adverse events in the 1.5 mg/m2 dose group compared to two in the placebo group and two in the 30 mg/m2 group. All SAEs were deemed by the investigators as not drug-related. “We are obviously delighted with the results,” said George Tidmarsh, President and CEO of La Jolla Pharmaceutical (NASDAQ:LJPC). “We hope to use these results as a platform for further investigation not only in chronic kidney disease but also in other diseases where tissue fibrosis plays a central role.”

Medifast (NYSE:MED) is lower in late trading Monday after the company reported mixed financial results for Q4, and provided Q1 guidance below analysts’ expectations, plus a mixed FY14 outlook. Shares are down 1.84% at $24.50, with a 52-week range of $21.75 – $29.47. Medifast (NYSE:MED) reported Q4 earnings of $0.39 per share, compared with the prior-year period’s $0.13 per share. Revenue was $77.3 million, down from $83.24 million in the same quarter last year. Analysts polled by Capital IQ were expecting EPS of $0.37 on revenues of $80.57 million. The company expects Q1 EPS of $0.32 – $0.35 on revenues of $86 million – $88 million. The Street view is EPS of $0.49 on revenues of $96.79 million. For fiscal 2014, Medifast (NYSE:MED) said it sees EPS of $1.80 – $1.90, versus the Street view of $1.96, and revenue of $340 million – $380 million, versus the consensus of $372.49 million.

 

 

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone